Thanks to our fearless leader Nicholas Genes, Grand Rounds is going strong. That’s the weekly roundup of what’s happening in the medical blogosphere. I’ll be hosting here next Tuesday, Feb. 5, with an emphasis on… you guessed it, Health 2.0.
This means we’re showcasing anything having to do with:
Consumers & health care providers working together in new and powerful ways
Helping consumers become empowered and knowledgeable
Making health care more cost-efficient
Price and quality…
Ricocheting around the press and the blogosphere:
1) Statins for all diabetics – One-third fewer people with diabetes (type 1 or type 2) would suffer heart attacks or strokes if they took cholesterol-lowering statin drugs, a U.K. study says. If you’re over 40, and not already on a statin, you’re urged to get on one. The experts say it’s like wearing a helmet for protection when you’re riding a bike. Sounds good, but there are…
So I really don’t need to say “I told you so” on the whole Exubera flop business. It was just so darn obvious.
I don’t know if anybody noticed, but the Indy Star article (local newspaper for both the affected Pfizer plant and competitor Eli Lilly) actually quotes me, saying “It’s not just about the funny looks you might get… This is something you need to carry everywhere, to every bathroom, every bedroom, every time…
You could say we’ve spurred a national debate here with the patient-led push for improved diabetes technology. But the term “debate” implies argument, and happily, most people seem to agree that “more is more”: the more attention paid to developing better technology, the more often better technology will be developed.
Check out this blogosphere/media coverage of Adaptive Path’s answer to my call for cooler diabetes devices:
NPR’s Future Tense
Friends, I am absolutely giddy over all the discussion spurred by yesterday’s Open Letter to Steve Jobs. The idea was to push the issue of medical device design vs. consumer “lifestyle” design to the forefront, i.e. raise a red flag to the tech-design community that can help us, and get people people talking. I’d say we accomplished that with flying colors. Michael Arrington’s post over at TechCrunch resonated throughout the blogosphere.
There were those who…